Boala Alzheimer și alte forme de demență.
73 de articolePreliminary research presented at the European Academy of Neurology Congress 2026 shows that exposure to extreme temperatures is associated with increased emergency department visits among people with dementia. This highlights environmental vulnerability as an important health and safety consideration for dementia patients.
Research identifies Arc, a native brain protein, as a mediator of toxic tau spread between neurons via extracellular vesicles in Alzheimer's disease. While Arc enables sick neurons to survive longer by expelling tau aggregates, it also paradoxically promotes pathology transmission to healthy cells, suggesting the extracellular space as a potential therapeutic intervention point.
This review examines the relationship between loneliness and social isolation as major risk factors for Alzheimer's disease and cognitive decline, with particular attention to sex differences. The authors discuss mechanisms linking isolation to AD pathology and propose approaches for developing prevention and treatment strategies based on understanding these associations.
Researchers developed a tablet-based software application designed to slow cognitive and communicative decline in individuals with Alzheimer's disease for home use. A randomized controlled trial with 32 participants (mild, moderate, and severe stages) compared outcomes between those using the application plus pharmacological treatment versus pharmacological treatment alone.
This health economics study examines costs associated with using neuroimaging (PET and MRI) to identify Alzheimer's disease patients most likely to benefit from lecanemab treatment over three years. The authors highlight a critical concern: approximately 78% of patients with mild cognitive impairment do not progress to dementia, making prophylactic treatment in all MCI patients costly and ethically problematic; they identify combined fluorodeoxyglucose and MRI imaging as the most cost-efficient approach at $177,000 per positive outcome with adjusted lecanemab pricing.
Disease-modifying Alzheimer's drugs provide hope for some patients, though their efficacy varies. The article emphasizes that dementia care must extend beyond pharmacological interventions to preserve quality of life and human dignity for all affected individuals, regardless of medication response.
